Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...
Crispr Therapeutics AG: Strategic Pipeline Progress and Financial Strength Drive Buy Rating
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.
bovnews21h
Crispr Therapeutics AG (CRSP) Stock Price Reaches $38.85: What Factors Are Influencing This Level?
Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...
technologynetworks23h
Library of Organoid “Mini-Guts” Helps Identify New Pathways in IBD
Technology Networks spoke with Dr. Thomas Dennison, University of Cambridge, to learn more about the advantages of using ...